A U.K. team has engineered an oncolytic virus with regulatory elements that target it specifically to hypoxic prostate cancer cells. It remains unclear whether relying on hypoxic regulation as the only homing determinant will be sufficient in metastatic tumors, which are much smaller than solid tumors and not overtly hypoxic.